APAC Diabetic Neuropathy Market

APAC Diabetic Neuropathy Market Size (2023 to 2028)

The size of the APAC diabetic neuropathy market is predicted to be worth USD 1.15 billion in 2023 and USD 1.96 billion by 2028, growing at a CAGR of 11.18% during the forecast period.

Diabetic neuropathy is a nervous disorder associated with diabetes mellitus. Neuropathy is seen as a common complication for both type 1 and type 2 diabetes.

The major problems in diabetic neuropathy include Diabetic Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy. Heart rate, blood pressure, perspiration, and digestion are all affected by diabetic automatic neuropathy. The thighs, hips, buttocks, and legs are affected by proximal diabetic neuropathy. Because of the persistent pain associated with diabetic neuropathy, daily activities might be tough.

According to a study published in the journal Diabetes Research and Clinical Practice, an estimated 477 million people will be living with diabetes by 2050. Diabetes affected around one-tenth of the world's population in 2019. Neuropathy affects between 62 percent and 72 percent of patients with diabetes. For more than 25 years, patients with neuropathy have had the highest prevalence of the condition. As a result, the treatment of diabetes has increased, with huge pharmaceutical companies investing considerably in new diabetic medications.

The link between neuropathy and diabetes has been established, and it has been determined that the majority of people with clinically confirmed diabetes are at high risk of developing neuropathy. Furthermore, according to an Asia-Pacific study published in the journal of neurology, 50 percent of people with diabetes have or will have peripheral neuropathy at some point in their lives. Diabetic neuropathy monitoring and treatment technologies and drugs to regulate and calm increased blood sugar levels are now on the market. Rising public awareness of diabetics and their long-term repercussions are expected to drive the growth of the APAC diabetic neuropathy market during the forecast period.

However, High clinical trial failure rates and stringent government requirements for product approval limit the Diabetic Neuropathy industry in the Asia Pacific.

Factors such as the increased need for better neuropathy treatments are expected to drive market expansion in the near future. In addition, many local governments and non-governmental organizations (NGOs) across the Asia Pacific are initiating efforts to raise awareness about diabetic neuropathy prevention. For example, the National Institute of Neurological Disorders and Stroke funds research into neuropathy and related issues.

The drugs used to treat neuropathic pain have had varied successes in terms of pain relief. However, the erroneous diagnosis or therapy selection, as well as side effects and the rising cost of drugs for the treatment of diabetic neuropathy, are all obstacles in the Diabetic Neuropathy Market. According to the Asian Pacific Association of Neuropathy with Diabetes, most people with clinically diagnosed diabetes diseases are at high risk of developing neuropathy.

This research report on the APAC diabetic neuropathy market has been segmented and sub-segmented into the following categories:

By Disorder:

• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

By Treatment:

• Drugs
  • Analgesic
    • Topical
      • Capsaicin
      • Others
    • Opioid:
      • Morphine
      • Others
    • NSAIDs
      • Ibuprofen
      • Naproxen
      • Others
  • Antidepressants:
    • TCAs
      • Amitriptyline
      • Imipramine
      • Others
    • SNRIs
      • Duloxetine
      • Others
    • SSRIs
      • Citalopram
      • Paroxetine
      • Others
  • Anticonvulsant Drugs
    • Gabapentin
    • Pregabalin
    • Topiramate
    • Others
    • Other Drugs
• Radiotherapy
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Others
  • Physiotherapy

By Distribution Channel:

• Hospitals
• Clinics
• Retail Pharmacy
• Online Pharmacy

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand, Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

The APAC Diabetic Neuropathy Market is expected to grow rapidly in the next years. Rising diabetes incidence and an increase in the geriatric population suffering from chronic disease are driving the diabetic neuropathy market in Asia. As a result, the Asia-Pacific region is predicted to develop at a compound annual growth rate of 7.7%. (CAGR). More than 60% of people with diabetes live in Asia, with China and India accounting for more than half of them. Hospitals equipped with X-ray machines to treat diabetic neuropathies are becoming more common as a result of an increase in healthcare awareness programs and a large number of patients. Furthermore, the growing number of diabetic patients in developing nations such as China, India, and Japan are expected to propel the APAC Diabetic Neuropathy Market forward. 

China held the largest share of the Diabetic Neuropathy market, and it is projected to account for a predominant share during the forecast period. The market growth is due to the proliferation of chronic diseases such as diabetes, the growing geriatric population, and favorable reimbursement policies. 

KEY MARKET PLAYERS:

Johnson & Johnson (Janssen Global Services, LLC), Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Lupin Limited, Pfizer Inc., Astellas Pharma Inc., Glenmark Pharmaceuticals Ltd., Arbor Pharmaceuticals, LLC and Depomed, Inc. are a few of the promising players in the APAC diabetic neuropathy market.